GMFB and neurodegenerative disease: In conclusion, our present preliminary study suggest that activation of mast cells by GMF, MPP+ and α-synuclein and release of proinflammatory and neurotoxic mediators along with the expression of GMF by mast cells indicate new therapeutic target for neurodegenerative diseases including Parkinson’s disease.